The patients not treated with β-blockers had higher values of MMP-2 [245.4 (197.4–299.4) ng/mL] in comparison with the controls (p = 0.015), and especially with the β-blockers (+) group (p = 0.006); see Figure 2A. The median of TIMP-2 was significantly lower in CKD patients treated with β-blockers [84.5 (74.0–103.0 ng/mL)] than in controls [96.5 (90.0–105.5) ng/mL], p = 0.025. This evidence concerns the gene TIMP2 and chronic kidney disease.